zum Inhalt springen

Fachbereich Veterinärmedizin


Service-Navigation

    Publikationsdatenbank

    A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model (2020)

    Art
    Zeitschriftenartikel / wissenschaftlicher Beitrag
    Autoren
    Kreye, Jakob
    Momsen Reincke, S.
    Kornau, Hans-Christian
    Sánchez-Sendin, Elisa
    Corman, Victor Max
    Liu, Hejun
    Yuan, Meng
    Wu, Nicholas C.
    Zhu, Xueyong
    Lee, Chang-Chun D.
    Trimpert, Jakob (WE 5)
    Höltje, Markus
    Dietert, Kristina (WE 12)
    Stöffler, Laura
    von Wardenburg, Niels
    van Hoof, Scott
    Homeyer, Marie A.
    Hoffmann, Julius
    Abdelgawad, Azza (WE 5)
    Gruber, Achim D. (WE 12)
    Bertzbach, Luca D. (WE 5)
    Vladimirova, Daria (WE 5)
    Li, Lucie Y.
    Barthel, Paula Charlotte
    Skriner, Karl
    Hocke, Andreas C.
    Hippenstiel, Stefan
    Witzenrath, Martin
    Suttorp, Norbert
    Kurth, Florian
    Franke, Christiana
    Endres, Matthias
    Schmitz, Dietmar
    Jeworoswski, Lara Maria
    Richter, Anja
    Schmidt, Marie Luisa
    Schwarz, Tatjana
    Müller, Marcel Alexander
    Drosten, Christian
    Wendisch, Daniel
    Sander, Leif E.
    Osterrieder, Nikolaus (WE 5)
    Wilson, Ian A.
    Prüss, Harald
    Quelle
    Cell
    Bandzählung: 183
    Heftzählung: 4
    Seiten: 1058 – 1069.e19
    ISSN: 0092-8674
    Sprache
    Englisch
    Verweise
    URL (Volltext): https://www.sciencedirect.com/science/article/pii/S0092867420312460
    DOI: 10.1016/j.cell.2020.09.049
    Pubmed: 33058755
    Kontakt
    Institut für Tierpathologie

    Robert-von-Ostertag-Str. 15
    14163 Berlin
    +49 30 838 62450
    pathologie@vetmed.fu-berlin.de

    Abstract / Zusammenfassung

    The emergence of SARS-CoV-2 led to pandemic spread of coronavirus disease 2019 (COVID-19), manifesting with respiratory symptoms and multi-organ dysfunction. Detailed characterization of virus-neutralizing antibodies and target epitopes is needed to understand COVID-19 pathophysiology and guide immunization strategies. Among 598 human monoclonal antibodies (mAbs) from 10 COVID-19 patients, we identified 40 strongly neutralizing mAbs. The most potent mAb, CV07-209, neutralized authentic SARS-CoV-2 with an IC50 value of 3.1 ng/mL. Crystal structures of two mAbs in complex with the SARS-CoV-2 receptor-binding domain at 2.55 and 2.70 Å revealed a direct block of ACE2 attachment. Interestingly, some of the near-germline SARS-CoV-2-neutralizing mAbs reacted with mammalian self-antigens. Prophylactic and therapeutic application of CV07-209 protected hamsters from SARS-CoV-2 infection, weight loss, and lung pathology. Our results show that non-self-reactive virus-neutralizing mAbs elicited during SARS-CoV-2 infection are a promising therapeutic strategy.